{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T22:30:59Z","timestamp":1785364259476,"version":"3.55.0"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Bimekizumab is the latest monoclonal antibody approved for the management of moderate-to-severe plaque psoriasis. Currently, data investigating its use in real-world settings are limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To assess the efficacy and safety of bimekizumab, also comparing patients who are biologic-naive vs. biologic-experienced.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A short-term (16 weeks) real-world monocentric prospective study was undertaken.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Globally, 56 patients were included. At baseline, mean Psoriasis Activity Severity Index (PASI) and Dermatology Life Quality Index (DLQI) were 16.9 (SD 7.8) and 22.6 (SD 5.9), respectively. A \u2265 75%\/\u2265 90%\/100% reduction in PASI (PASI 75\/90\/100) were reached by 77% (43\/56)\/50% (28\/56)\/43% (43\/56) of patients at week 4 and by 88% (49\/56)\/82% (46\/56)\/70% (39\/56) of patients at week 16. In our cohort of 56 people, 29 (52%) patients were biologic-naive whereas 27 (48%) were biologic-experienced. At baseline, both PASI and DLQI were significantly higher in the biologic-naive group compared with the biologic-experienced group [PASI 19.4 (SD 7.7) vs. 14.2 (SD 7.0), P &amp;lt; 0.05; DLQI: 25.3 (SD 4.5) vs. 19.7 (SD 6.0), P &amp;lt; 0.001]. Although not significant, a higher percentage of patients in the biologic-naive group compared with the biologic-experienced group reached PASI 75 (79% vs. 63%, P = 0.18), PASI 90 (62% vs. 44%, P = 0.19) and PASI 100 (48% vs. 37%, P = 0.40) at week 4. However, the percentage of PASI 75\/90\/100 response were similar between the two groups at week 16. Regarding safety, three candidiasis (5%) and one (2%) eczematous reaction were reported, without differences between the two groups. Finally, two (4%) bimekizumab discontinuation because of treatment failure and three (5%) for AEs were collected.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our study confirmed the efficacy and safety of bimekizumab, suggesting that the previous failure of biologics does not seem to affect its therapeutic effectiveness.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ced\/llae147","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T19:28:23Z","timestamp":1713814103000},"page":"1186-1189","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and safety of bimekizumab in real-world psoriasis management: data from patients who are biologic-naive vs. biologic-experienced"],"prefix":"10.1093","volume":"49","author":[{"given":"Matteo","family":"Megna","sequence":"first","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4658-7391","authenticated-orcid":false,"given":"Angelo","family":"Ruggiero","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginevra","family":"Torta","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2523-050X","authenticated-orcid":false,"given":"Fabrizio","family":"Martora","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariateresa","family":"Bianco","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5940-0592","authenticated-orcid":false,"given":"Luca","family":"Potestio","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,24]]},"reference":[{"key":"2024091818145514000_llae147-B1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/14740338.2023.2218086","article-title":"Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation","volume":"22","author":"Ruggiero","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"2024091818145514000_llae147-B2","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s40265-021-01612-z","article-title":"Bimekizumab for the treatment of psoriasis","volume":"81","author":"Freitas","year":"2021","journal-title":"Drugs"},{"key":"2024091818145514000_llae147-B3","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/jocd.15543","article-title":"A case of erythrodermic psoriasis rapidly and successfully treated with Bimekizumab","volume":"22","author":"Megna","year":"2023","journal-title":"J\u00a0Cosmet Dermatol"},{"key":"2024091818145514000_llae147-B4","doi-asserted-by":"crossref","first-page":"e15952","DOI":"10.1111\/dth.15952","article-title":"Sub-erythrodermic psoriasis successfully treated with bimekizumab: a case report","volume":"35","author":"Valenti","year":"2022","journal-title":"Dermatol Ther"},{"key":"2024091818145514000_llae147-B5","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/12034754231217205","article-title":"Real-world experience using bimekizumab for the treatment of moderate-to-severe psoriasis from a single outpatient dermatology clinic","volume":"28","author":"Cirone","year":"2024","journal-title":"J Cutan Med Surg"},{"key":"2024091818145514000_llae147-B6","doi-asserted-by":"crossref","first-page":"1243843","DOI":"10.3389\/fmed.2023.1243843","article-title":"Effectiveness and safety of Bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis)","volume":"10","author":"Gargiulo","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2024091818145514000_llae147-B7","doi-asserted-by":"crossref","first-page":"e2024052","DOI":"10.5826\/dpc.1402a52","article-title":"Bimekizumab for the treatment of plaque psoriasis with involvement of genitalia: a 16-week multicenter real-world experience \u2013 IL PSO (Italian Landscape Psoriasis)","volume":"14","author":"Orsini","year":"2024","journal-title":"Dermatol Pract Concept"},{"key":"2024091818145514000_llae147-B8","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1111\/ijd.15644","article-title":"Real-world experience versus clinical trials: pros and cons in psoriasis therapy evaluation","volume":"61","author":"Cinelli","year":"2022","journal-title":"Int J Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae147\/58379019\/llae147.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/10\/1186\/59183603\/llae147.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/10\/1186\/59183603\/llae147.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T18:15:08Z","timestamp":1726683308000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/49\/10\/1186\/7657102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,24]]},"references-count":8,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,4,24]]},"published-print":{"date-parts":[[2024,9,18]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae147","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,4,24]]}}}